281 related articles for article (PubMed ID: 2783611)
1. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
Da Prada M; Kettler R; Keller HH; Burkard WP; Muggli-Maniglio D; Haefely WE
J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611
[TBL] [Abstract][Full Text] [Related]
2. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K
J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
[TBL] [Abstract][Full Text] [Related]
3. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.
Kettler R; Da Prada M; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():101-2. PubMed ID: 2248058
[TBL] [Abstract][Full Text] [Related]
4. Short-lasting and reversible inhibition of monoamine oxidase-A by moclobemide.
Da Prada M; Kettler R; Keller HH; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():103-5. PubMed ID: 2248059
[TBL] [Abstract][Full Text] [Related]
5. Monoamine oxidase inhibition by moclobemide and 2-amino-ethyl carboxamide derivatives: mode of action and kinetic characteristics.
Cesura AM; Muggli-Maniglio D; Lang G; Imhof R; Da Prada M
J Neural Transm Suppl; 1990; 32():165-70. PubMed ID: 2089085
[TBL] [Abstract][Full Text] [Related]
6. Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491.
Keller HH; Kettler R; Keller G; Da Prada M
Naunyn Schmiedebergs Arch Pharmacol; 1987 Jan; 335(1):12-20. PubMed ID: 3574489
[TBL] [Abstract][Full Text] [Related]
7. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
Da Prada M; Kettler R; Keller HH; Burkard WP; Haefely WE
J Neural Transm Suppl; 1989; 28():5-20. PubMed ID: 2677242
[TBL] [Abstract][Full Text] [Related]
8. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors.
Alemany R; Olmos G; García-Sevilla JA
Br J Pharmacol; 1995 Feb; 114(4):837-45. PubMed ID: 7773544
[TBL] [Abstract][Full Text] [Related]
9. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile.
Curet O; Damoiseau G; Aubin N; Sontag N; Rovei V; Jarreau FX
J Pharmacol Exp Ther; 1996 Apr; 277(1):253-64. PubMed ID: 8613928
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
[TBL] [Abstract][Full Text] [Related]
11. From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors.
Da Prada M; Kettler R; Keller HH; Cesura AM; Richards JG; Saura Marti J; Muggli-Maniglio D; Wyss PC; Kyburz E; Imhof R
J Neural Transm Suppl; 1990; 29():279-92. PubMed ID: 2193111
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
Wiesel FA; Raaflaub J; Kettler R
Eur J Clin Pharmacol; 1985; 28(1):89-95. PubMed ID: 3987791
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
Burkard WP; Bonetti EP; Da Prada M; Martin JR; Polc P; Schaffner R; Scherschlicht R; Hefti F; Müller RK; Wyss PC
J Pharmacol Exp Ther; 1989 Jan; 248(1):391-9. PubMed ID: 2913284
[TBL] [Abstract][Full Text] [Related]
14. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
Gerardy J
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
[TBL] [Abstract][Full Text] [Related]
15. Brain microdialysis in rats: a technique to reveal competition in vivo between endogenous dopamine and moclobemide, a RIMA antidepressant.
Colzi A; d'Agostini F; Cesura AM; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S17-20. PubMed ID: 1546133
[TBL] [Abstract][Full Text] [Related]
16. An iodinated derivative of moclobemide as potential radioligand for brain MAO-A exploration.
Rafii H; Chalon S; Ombetta JE; Frangin Y; Pourcelot L; Besnard JC; Bodard S; Guilloteau D
Life Sci; 1996; 58(14):1159-69. PubMed ID: 8614267
[TBL] [Abstract][Full Text] [Related]
17. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
Urichuk LJ; Allison K; Holt A; Greenshaw AJ; Baker GB
J Affect Disord; 2000 May; 58(2):135-44. PubMed ID: 10781703
[TBL] [Abstract][Full Text] [Related]
18. Biochemistry and pharmacology of moclobemide, a prototype RIMA.
Haefely W; Burkard WP; Cesura AM; Kettler R; Lorez HP; Martin JR; Richards JG; Scherschlicht R; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S6-14. PubMed ID: 1546143
[TBL] [Abstract][Full Text] [Related]
19. Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide.
Cesura AM; Kettler R; Imhof R; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S15-6. PubMed ID: 1546132
[TBL] [Abstract][Full Text] [Related]
20. Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat.
Kan JP; Mouget-Goniot C; Worms P; Biziere K
Biochem Pharmacol; 1986 Mar; 35(6):973-8. PubMed ID: 3954800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
